Skip to content

Search

Showing results for "1"

Wellbeing study needs you!

Young people are needed for a new Children's Diabetes Centre research study that aims to improve the mental health of teens with type 1 diabetes.

Research finds pumps deliver better long-term blood glucose control

New research from the Children’s Diabetes Centre at The Kids Research Institute Australia has found children who use an insulin pump to manage their type 1 diabetes have better long-term blood glucose control than those on insulin injections.

JRDF One Walk

Patients, families and our centre staff members took part in JDRF's One Walk last October to raise funds for type 1 diabetes research.

An adapted novel flow cytometry methodology to delineate types of cell death in airway epithelial cells

An adapted novel flow cytometry methodology to delineate types of cell death in airway epithelial cells Cystic fibrosis (CF) lung disease is

Scientific Advisory Committee

The Scientific Advisory Committee's (SAC) role is to provide scientific direction and to ensure the objectives of WAERP are reflected in the research performed; SAC forms part of our governance structure.

Exercise

Our research focuses on what are the best ways for patients with type 1 diabetes to exercise safely.

School excursions at The Kids Research Institute Australia

Hey teachers and educators - the The Kids Discovery Centre schools pilot program is returning in 2021!

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)

Pneumococcal disease (PD) remains a major health concern globally. In children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ and public health important serotypes 22F and 33F. This phase 3 study evaluated safety and immunogenicity of mixed PCV13/V114 regimens using a 3 + 1 dosing schedule when changing from PCV13 to V114 at doses 2, 3, or 4. 

Service availability

Are you tired of being on waitlists to access supports for your family? CliniKids has immediate availability for a number of therapies and programs in clinic (Subiaco and Joondalup) or via telehealth.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia

We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adults.